Skip to Content
Merck
CN
  • Partial effects of the protein kinase C inhibitor chelerythrine in a battery of tests for manic-like behavior in black Swiss mice.

Partial effects of the protein kinase C inhibitor chelerythrine in a battery of tests for manic-like behavior in black Swiss mice.

Pharmacological reports : PR (2014-06-21)
Haim Einat
ABSTRACT

The inhibition of protein kinase C (PKC) was recently suggested as a novel approach for the development of mood stabilizing drugs. To further evaluate this possibility, the aim of the present study was to test the effects of peripheral (intraperitoneal) administration of chelerythrine in a battery of mania-related behavioral tests in black Swiss mice, a strain specific battery that was previously demonstrated to distinguish differential effects of mood stabilizing drugs. Sub-chronic administration of 1.0mg/kg or 2.0mg/kg chelerythrine had marginal effects to reduce spontaneous activity and sweet solution preference in black Swiss mice which naturally show mania-like behaviors. Chelerythrine had no effects on the behavior of these mice in the elevated plus-maze, the forced swim test and the amphetamine-induced hyperactivity test. The partial effects in the battery are not unique as previous studies showed that lithium, valproate and risperidone, all used in the treatment of bipolar disorder, have distinct profiles in the battery. It is therefore concluded that chelerythrine may have antimanic effects and additional dose and time response studies are warranted to further evaluate its range of activity.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Saccharin, ≥99%
Sigma-Aldrich
Saccharin, ≥98%
Supelco
Saccharin, Pharmaceutical Secondary Standard; Certified Reference Material
Saccharin, European Pharmacopoeia (EP) Reference Standard
USP
Saccharin, United States Pharmacopeia (USP) Reference Standard
Supelco
Mettler-Toledo Calibration substance ME 51143091, Saccharin, traceable to primary standards (LGC)